Model DetailsLung adenoma
Model Name |
Lung adenoma | Strain |
CD-1 |
Tumor Inducing Agent(s) |
None (spontaneous) |
Tumor Synonyms |
lung adenoma • alveolar-bronchiolar adenoma • lung, bronchiolo-alveolar adenoma • lung, adenoma, bronchiolar-alveolar • lung neoplasm • lung tumor • bronchiolo-alveolar adenoma • lung, alveolar-bronchiolar adenoma |
Strain Synonyms |
outbred CD-1 • Swiss CD-1® • CD1 nontransgenic • Charles River CD-1 • Swiss CD-1 • Crl:CD-1®(ICR) • outbred CD1 • (Swiss) CD-1 • CD1 • Crl:CD-1(ICR)BR • ICR Crj:CD-1 • random-bred Crl:CD-1(ICR)BR • CD-1 outbred • Crl:CD-1 (ICR) BR • Crj:CD-1(ICR) • ICR(CD-1) • Crl: CD-1 (ICR) BR • ICR |
| Organ Affected | Sex | Frequency | Age Of Detection | Additional Information Expand all Collapse all | Reference |
|---|---|---|---|---|---|
| Lung | Male |
very low |
|
Takahashi O, Toxicology 1997 Dec 26;124(2):95-103 | |
| Lung | Female |
2.0% (1 of 50 mice) |
|
Takahashi O, Toxicology 1997 Dec 26;124(2):95-103 | |
| Lung | Male |
9.8% (5 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
17.1% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
15.7% (8 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
22.2% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
17.6% (9 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
10% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
17.6% (9 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
9.7% |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
13.7% (7 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
11.7% (7 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
11.8% (8 of 68 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
23.5% (12 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
20% (12 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Male |
23.5% (16 of 68 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
9.8% (5 of 51 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
5.0% (3 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
11.7% (7 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
10% (6 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
4.5% (1 of 22 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
13.3% (8 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
6.7% (4 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
3.3% (2 of 60 mice) |
|
Baldrick P, Toxicol Pathol 2007;35(4):562-9 | |
| Lung | Female |
15% (5 of 33 mice) |
90 weeks |
|
Waalkes MP, Cancer Res 2006 Feb 1;66(3):1337-45 |
| Lung | Male |
19.3% (140 of 725 mice) |
|
Chandra M, Toxicol Lett 1992 Jun;61(1):67-74 | |
| Lung | Female |
12.3% (89 of 725 mice) |
|
Chandra M, Toxicol Lett 1992 Jun;61(1):67-74 | |
| Lung | Male |
14.6% (130 of 891 mice) |
up to 109 weeks |
|
Maita K, Toxicol Pathol 1988;16(3):340-9 |
| Lung | Female |
14.5% (129 of 890 mice) |
up to 109 weeks |
|
Maita K, Toxicol Pathol 1988;16(3):340-9 |
| Lung | Male |
12% (7 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Male |
8.3% (5 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Female |
13% (8 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Female |
5.0% (3 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Male |
12% (7 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Female |
10% (6 of 60 mice) |
|
Tannehill-Gregg SH, Toxicol Sci 2007 Jul;98(1):258-70 | |
| Lung | Male |
3.2% (1 of 31 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
12.5% (2 of 16 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
40% (2 of 5 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
19.0% (4 of 21 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Male |
9.6% (5 of 52 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
9.7% (3 of 31 mice) |
180-400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
0% (0 of 12 mice) |
401 - ~725 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
18.2% (2 of 11 mice) |
~730 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
8.7% (2 of 23 mice) |
>400 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Female |
9.3% (5 of 54 mice) |
>180 days |
|
Diwan BA, Toxicol Appl Pharmacol 1999 Nov 15;161(1):82-99 |
| Lung | Mixed Population |
observed |
≥1 year |
|
Brayton CF, Vet Pathol 2012 Jan;49(1):85-105 |
| Lung | Male |
0% (0 of 1453 mice) |
up to 43 weeks |
|
Son WC, Toxicol Lett 2003 Nov 1;145(1):88-98 |
| Lung | Male |
0.07% (1 of 1453 mice) |
up to 50 weeks |
|
Son WC, Toxicol Lett 2003 Nov 1;145(1):88-98 |